Security
NLS Pharmaceutics Ltd. Ordinary Shares · NLSP
NLSPNASDAQCommon stockHistorical · closed Oct 30, 2025CIK 1783036Updated Nov 6, 2026
Name history
NLS Pharmaceutics Ltd. · through Oct 30, 2025
Current security for this SEC filerNCEL · NASDAQ
NLSP price & chart
Historical security
This listing closed Oct 30, 2025. Live provider charts are shown only for current listings.
Current security: NCEL
About the company
NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the Company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| AssetsUSD | 4,337,628Source | 1,193,458Source | 2,270,146Source | 2,058,049Source | 8,269,095Source | — | 11,445,000Source | 2,233,125Source | 1,846,641Source | 9,276,643Source |
| Property, Plant and Equipment, NetUSD | 5,303Source | 990Source | 12,398Source | 23,806Source | 27,733Source | — | 95,000Source | 7,290Source | 6,694Source | 18,102Source |
| GoodwillUSD | — | — | — | — | — | — | 1,731,000Source | — | — | — |
| Current assets: | ||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,072,376Source | 552,758Source | 1,651,452Source | 1,354,187Source | 7,092,115Source | — | 2,201,000Source | 1,665,395Source | 897,680Source | 8,948,400Source |
| Assets, CurrentUSD | 4,035,887Source | 1,192,468Source | 2,245,190Source | 2,022,508Source | 8,241,362Source | — | 3,182,000Source | 2,225,552Source | 1,823,062Source | 9,246,398Source |
| Prepaid Expense and Other Assets, CurrentUSD | 963,511Source | 639,710Source | 593,738Source | 668,321Source | 1,149,247Source | — | 981,000Source | 560,157Source | 925,382Source | 297,998Source |
| Other Assets, NoncurrentUSD | 283Source | — | 12,558Source | 11,735Source | — | — | — | 283Source | 16,885Source | 12,143Source |
| LIABILITIES AND EQUITY | ||||||||||
| LiabilitiesUSD | 1,455,121Source | 10,461,716Source | 6,556,963Source | 6,099,523Source | 4,020,140Source | — | 4,195,000Source | 826,764Source | 10,680,204Source | 5,995,804Source |
| Stockholders’ equity: | ||||||||||
| Preferred Stock, Value, IssuedUSD | 42,539Source | — | — | — | — | — | — | 2,740,958Source | — | — |
| Common Stock, Value, IssuedUSD | 153,141Source | 808,555Source | 733,413Source | 411,268Source | 259,729Source | — | 291,000Source | 166,353Source | 733,413Source | 668,555Source |
| Additional Paid in CapitalUSD | 77,361,856Source | — | 60,925,046Source | 45,962,126Source | 38,532,118Source | — | 93,691,000Source | 72,820,671Source | 61,029,437Source | 60,864,530Source |
| Retained Earnings (Accumulated Deficit)USD | -74,805,306Source | -72,409,318Source | -65,814,193Source | -50,346,584Source | -34,363,039Source | — | -84,891,000Source | -74,430,474Source | -70,373,484Source | -58,201,455Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 108,853Source | 4,207Source | -66,225Source | -32,712Source | -179,853Source | — | — | 108,853Source | -158,071Source | -50,791Source |
| Stockholders' Equity Attributable to ParentUSD | 2,882,507Source | -9,268,258Source | -4,286,817Source | -4,041,474Source | 4,248,955Source | -7,333,640Source | 7,250,000Source | 1,406,361Source | -8,833,563Source | 3,280,839Source |
| Liabilities and EquityUSD | 4,337,628Source | 1,193,458Source | 2,270,146Source | 2,058,049Source | 8,269,095Source | — | 11,445,000Source | 2,233,125Source | 1,846,641Source | 9,276,643Source |
| Current liabilities: | ||||||||||
| Liabilities, CurrentUSD | — | 7,718,117Source | 3,892,374Source | 3,410,793Source | 1,192,851Source | — | 4,195,000Source | 826,764Source | 7,919,550Source | 3,359,713Source |
| Accounts Payable, CurrentUSD | 1,021,052Source | 4,584,284Source | 3,113,025Source | 2,521,857Source | 527,203Source | — | — | 515,486Source | 4,633,534Source | 2,373,276Source |
| Additional Financial Items | ||||||||||
| Accrued Liabilities, CurrentUSD | — | — | 779,349Source | 534,600Source | 665,648Source | — | 880,000Source | — | 1,652,270Source | 986,437Source |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD | — | — | — | — | — | — | — | 108,853Source | -158,073Source | — |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | — | 264,997Source |
| Deferred Revenue, NoncurrentUSD | — | — | 2,499,969Source | 2,499,969Source | 2,499,969Source | — | — | — | 2,499,969Source | 2,499,969Source |
| Additional Paid in Capital, Common Stock | — | —Source | — | — | — | — | — | — | — | — |
| Long-term Debt | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -16,495,680Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 765,000Source | — | — | 22,730Source |
| Changes in operating assets and liabilities: | ||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | -118,047Source | 2,260,258Source | 636,263Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 270,668Source | 852,486Source | 1,004,681Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,766,000Source | -4,267,884Source | -9,684,466Source | -13,879,371Source |
| Cash flows from investing activities: | ||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | -1,708,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 1,700,000Source | -3,917Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 8,000Source | 3,917Source | — | — |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,629,000Source | 5,039,516Source | 1,633,746Source | 17,396,669Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,551,000Source | 767,715Source | -8,050,720Source | 3,517,198Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,072,376Source | 552,758Source | 1,651,452Source | 1,354,187Source | 7,092,115Source | 145,404Source | 2,201,000Source | 1,665,395Source | 897,680Source | — |
| Supplemental disclosure of cash flow information: | ||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 20,000Source | 467Source | 145,153Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -12,000Source | — | — | -100Source |
| Additional Financial Items | ||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 765,000Source | 125,644Source | 164,906Source | — |
| DepreciationUSD | — | — | — | — | — | — | 55,000Source | 3,321Source | 11,408Source | 11,408Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | 1,348,000Source | 3,214,224Source | 5,898,775Source | 6,505,721Source |
| GoodwillUSD | — | — | — | — | — | — | 1,731,000Source | — | — | — |
| Insured Event, Gain (Loss)USD | — | — | — | — | — | — | — | -109,650Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | 45,054Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | — | -8,300,000Source | -1,980,810Source | -12,172,029Source | -16,495,680Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | 8,300,000Source | -4,056,990Source | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | -5,738,000Source | 2,399,303Source | — | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | 10,000,000Source | — | — |
| Operating ExpensesUSD | — | — | — | — | — | — | — | 4,380,113Source | 11,807,063Source | 15,482,364Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 92,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | -99,000Source | 49,351Source | -219,812Source | 10,045Source |
| Pension Cost (Reversal of Cost)USD | — | — | — | — | — | — | — | 6,239Source | 59,526Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 1,911,513Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 23,692Source |
income statement · annual statements
| Line item | Q2 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | -2,562,000Source | -4,380,113Source | -11,807,063Source | -15,482,364Source |
| Other Nonoperating Income (Expense)USD | — | -99,000Source | 49,351Source | -219,812Source | 10,045Source |
| Net Income (Loss) Attributable to ParentUSD | — | -8,300,000Source | -1,980,810Source | -12,172,029Source | -16,495,680Source |
| Earnings Per Share, BasicUSD per share | — | 2.16Source | -2.63Source | -0.32Source | -0.84Source |
| Earnings Per Share, DilutedUSD per share | — | 2.16Source | -2.63Source | -0.32Source | -0.84Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 3,843,984Source | 1,543,283Source | 38,176,020Source | 19,682,643Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 3,843,984Source | 1,543,283Source | 38,176,020Source | 19,682,643Source |
| Interest Expense (non-operating)USD | — | — | 45,054Source | — | — |
| Additional Financial Items | |||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 55,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | 1,348,000Source | 3,214,224Source | 5,898,775Source | 6,505,721Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | -8,300,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | 119,920Source | — |
| Interest Expense, DebtUSD | — | — | — | — | 95,211Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | 8,300,000Source | -4,056,990Source | — | — |
| Nonoperating Income (Expense)USD | — | -5,738,000Source | 2,399,303Source | — | — |
| Operating Costs and ExpensesUSD | — | — | 10,000,000Source | — | — |
| Operating ExpensesUSD | — | — | 4,380,113Source | 11,807,063Source | 15,482,364Source |
| Operating Lease, ExpenseUSD | — | 92,000Source | — | — | — |
| Other ExpensesUSD | 50,000Source | 88,000Source | 321,000Source | — | — |
| Other Operating IncomeUSD | — | — | — | — | 16,300,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 2,076,180Source | — | — |
| Research and Development ExpenseUSD | — | 1,126,000Source | 422,051Source | 5,908,288Source | 8,976,643Source |
Offerings
Registration 333-290516
Registration 333-298458
Registration 333-284811
Registration 333-295770
Filing attachments
ea031144001ex99-1.htm · 6-K · 2026-11-09
Exhibit 99.1 NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market The financing led by international healthcare investors, alongside The Crushing T1 Foundation, reinforces confidence in NewcelX’s strategy and long-term potential ZURICH, Switzerland, November 9, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into…
Read attachment ↗ea031065001ex99-1.htm · 6-K · 2026-11-04
Exhibit 99.1 NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments Transaction provides $500,000 upfront of which $30,000 is in cash and the remainder in shares, representing a 9.4% equity stake in REA Holdings, alongside potential worldwide royalties of up to 8% Strategic divestiture of legacy CVR assets supports NewcelX’s cell-therapy focus while preserving potentia…
Read attachment ↗ea030514101ex99-1.htm · 6-K · 2026-09-18
Exhibit 99.1 NEWCELX LTD. AND ITS SUBSIDIARIES INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Interim Consolidated Balance Sheets 2 Interim Consolidated Statements of Profit or Loss and Other Comprehensive Loss 3 Interim Statements of Changes in Shareholders’ Equity …
Read attachment ↗ea030514101ex99-2.htm · 6-K · 2026-09-18
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis should be read in conjunction with our unaudited interim condensed financial statements and related notes as of and for the six months ended June 30, 2026, included as Exhibit 99.1 to this Report on Form 6-K, or this Report. This discussion and other parts of the interim report contain forward-looking statements based upon current expectations that involve r…
Read attachment ↗ea030003402ex99-1.htm · 6-K · 2026-07-31
Exhibit 99.1 NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting ZURICH, Switzerland, July 31, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into securities purchase agre…
Read attachment ↗ea029793401ex99-1.htm · 6-K · 2026-07-15
Exhibit 99.1 NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio Brazil patent complements U.S. patent portfolio for NCEL-101, strengthening global position in the type 1 diabetes market ZURICH, Switzerland, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent Num…
Read attachment ↗